Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study

被引：2
|
作者：
O'Cearbhaill, R. E. [1 ,2 ]
Moore, K. N. [3 ,4 ]
Yeku, O. [5 ]
Liu, J. F. [6 ]
Bouberhan, S. [5 ]
Hamilton, E. P. [7 ]
Hou, J. Y. [8 ]
Van Nieuwenhuysen, E. [9 ]
Papadimitriou, K. [10 ]
Yoo, S-Y. [11 ]
Govindraj, S. [11 ]
Brouwer-Visser, J. [11 ]
Peterman, M. [11 ]
Schmidt, T. [11 ]
Barnes, B. [11 ]
Madia, P. [11 ]
Zhu, M. [11 ]
Uldrick, T. S. [11 ]
Miller, E. A. [11 ]
O'Malley, D. [12 ,13 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA
[4] Sarah Cannon Res Inst, Oklahoma City, OK USA
[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[6] Dana Farber Canc Inst, Med Oncol, Boston, MA USA
[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN 5 USA
[8] Columbia Univ, Div Gynecol Oncol, Med Ctr, New York, NY USA
[9] Leuven Canc Inst, Dept Oncol, Leuven, Belgium
[10] Univ Antwerp Hosp, Multidisciplinary Oncol Ctr Antwerp MOCA, Antwerp, Belgium
[11] Regeneron Pharmaceut Inc, Global Dev, Tarrytown, NY USA
[12] Ohio State Univ, Div Gynecol Oncol, Columbus, OH USA
[13] James Canc Ctr, Columbus, OH USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1933
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
754P
引用
收藏
页码：S516 / S517
页数：2
相关论文
共 50 条
  • [31] Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
    O'Malley, David M.
    Oaknin, Ana
    Monk, Bradley J.
    Selle, Frederic
    Rojas, Carlos
    Gladieff, Laurence
    Berton, Dominique
    Leary, Alexandra
    Moore, Kathleen N.
    Estevez-Diz, Maria D. P.
    Hardy-Bessard, Anne-Claire
    Alexandre, Jerome
    Opperman, Christina P.
    de Azevedo, Carla Rameri A. S.
    Randall, Leslie M.
    Feliu, Waldo Ortuzar
    Ancukiewicz, Marek
    Ray-Coquard, Isabelle
    GYNECOLOGIC ONCOLOGY, 2021, 163 (02) : 274 - 280
  • [32] Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
    Noboru Yamamoto
    Hiroshi Nokihara
    Yasuhide Yamada
    Takashi Shibata
    Yosuke Tamura
    Yoshitaka Seki
    Kazunori Honda
    Yuko Tanabe
    Hiroshi Wakui
    Tomohide Tamura
    Investigational New Drugs, 2017, 35 : 207 - 216
  • [33] Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Shibata, Takashi
    Tamura, Yosuke
    Seki, Yoshitaka
    Honda, Kazunori
    Tanabe, Yuko
    Wakui, Hiroshi
    Tamura, Tomohide
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (02) : 207 - 216
  • [34] Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
    Frentzas, Sophia
    Mislang, Anna Rachelle Austria
    Lemech, Charlotte
    Nagrial, Adnan
    Underhill, Craig
    Wang, Wenjing
    Wang, Zhongmin Maxwell
    Li, Baiyong
    Xia, Yu
    Coward, Jermaine I. G.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (04)
  • [35] Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies
    Aftimos, Philippe
    Rolfo, Christian
    Rottey, Sylvie
    Offner, Fritz
    Bron, Dominique
    Maerevoet, Marie
    Soria, Jean-Charles
    Moshir, Mahan
    Dreier, Torsten
    Van Rompaey, Luc
    Michot, Jean-Marie
    Silence, Karen
    Hultberg, Anna
    Gandini, Domenica
    de Haard, Hans
    Ribrag, Vincent
    Peeters, Marc
    Thibault, Alain
    Leupin, Nicolas
    Awada, Ahmad
    CLINICAL CANCER RESEARCH, 2017, 23 (21) : 6411 - 6420
  • [36] Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers
    Sakamuri, Divya
    Glitza, Isabella C.
    Cuellar, Sonia L. Betancourt
    Subbiah, Vivek
    Fu, Siqing
    Tsimberidou, Apostolia M.
    Wheler, Jennifer J.
    Hong, David S.
    Naing, Aung
    Falchook, Gerald S.
    Fanale, Michelle A.
    Cabanillas, Maria E.
    Janku, Filip
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (03) : 671 - 676
  • [37] Phase I, dose-escalation study of BIIB022 (anti-IGF-1R antibody) in advanced solid tumors
    von Mehren, M.
    Britten, C.
    Lear, K.
    Camidge, D. R.
    Wainberg, Z. A.
    Pieslor, P. C.
    Darif, M.
    Harris, S.
    Balogh, K.
    Leong, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors.
    Voskoboynik, Mark
    Richardson, Gary Edward
    Mileshkin, Linda R.
    McNeil, Catriona M.
    Horvath, Lisa
    Benedetti, Fabio M.
    Choy, Gavin S.
    Sankar, Neil
    McCurry, Shelly
    Zhang, Xiaoling
    Gao, Min
    Shah, Ajit K.
    Millward, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] EFFICACY AND SAFETY OF AK112, AN ANTI-PD-1/VEGFA BISPECIFIC ANTIBODY, IN PATIENTS WITH PLATINUM-RESISTANT/REFRACTORY EPITHELIAL OVARIAN CANCER IN A PHASE 1 STUDY
    Coward, Jermaine
    Frentzas, Sophia
    Mislang, Anna
    Gao, Bo
    Lemech, Charlotte
    Jin, Xiaoping
    Li, Baiyong
    Wang, Max
    Kwek, Kon Yew
    Zhou, Yiting
    Xia, Yu
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A457 - A457
  • [40] Phase I/II dose-escalation and expansion study of afuresertib plus carboplatin and paclitaxel in recurrent ovarian cancer.
    Blagden, Sarah Patricia
    Gabra, Hani
    Hamilton, Anne L.
    Wong, Shirley S.
    Michael, Agnieszka
    Mileshkin, Linda R.
    Hall, Marcia
    Goh, Jeffrey
    Lisyanskaya, Alla Sergeevua
    DeSilvio, Michelle
    Habr, Dany
    Gainer, Shelby
    Gopalakrishna, Prashanth
    Meniawy, Tarek
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345